预约演示
Boehringer Ingelheim posts more Jardiance growth as potential US kidney disease approval nears
2023-08-01
临床3期上市批准临床结果
Overall, Boehringer Ingelheim reported 9.7% growth in the first half of the year.
Gearing uBoehringer Ingelheimdiabetes and heart failure drug Jardiance in chronic kidney disease, Boehringer Ingelheim has already started 2023 by posting strong pharma sales growth.
The German drugmaker reporteddiabetesjump heart failureles over the first chronic kidney diseasethBoehringer Ingelheimi Lilly-partnered SGLT2 inhibitor Jardiance. Human pharmaceutical products made up 9.6 billion euros ($10.5 billion) of the total sales haul, good for 11.3% growth, with animal health products contributing the rest of Boehringer’s 12.2 billion euros ($13.2 billion) in total revenue.
The Jardiance franchise generated 3.5 billion euros ($3.83 billion) for Boehringer over this year’s first half. Looking forward, the comSGLT2expects further growth as Jardiance progresses in chronic kidney disease (CKD), with a U.S. decision expected to come later this year following a recent European Commission go-ahead. In a late-stBoehringer the drug was the first SGLT2 inhibitor to post a reduction in all-cause hospitalizations for CKD patients while reducing disease progression or death by 28% compared with placebo.
An FDA nod would add to Jardiance’s wide reach, which already includes TBoehringeretes and heart failure. Later this year, the company will report data from the drug's phase 3 trial in myocarchronic kidney disease (CKD)SGLT2CKD
AsiFDAfrom its Jardiance performance, Boehringer celebrated the fact thType 2 diabetesnew Rheart failureps. Those target fields such as cancer, immunology, fibrotic lung diseases and remyocardial infarction
Meanwhile, the company's PDE4B inhibitBoehringered into phase 3 trials in idiopathic pulmonary fibrosis and progressive pulmonary fibroscancerfibrotic lung diseasesretinal diseases
“Persistent and above-avePDE4B inhibitorPDE4Binvestments in our pipeline during the last idiopathic pulmonary fibrosisew trprogressive pulmonary fibrosisn the years to come, thus transforming lives for generations,” Boehringer's chairman of the board, Hubertus von Baumbach, noted in the company's release.
Elsewhere, Boehringer’s Humira biosimilar recently launched as the first interchangeable option in the U.S. The company is currently pricing the med 5% to 7% below Humira’s list price but will turn to a two-price strategy in 2024.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。